Glaukos Stock News

Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ: PODD ) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago quarter EPS of $0.17. The stock has a 52-week-high of $324.81 and a 52-week-low of $193.70. At the end of the last trading period, Insulet closed at $253.19. BTIG upgraded the previous rating for DexCom Inc (NASDAQ: DXCM ) from Neutral to Buy. DexCom earned $0.89 in the third quarter, compared to $0.94 in the year-ago quarter. The current stock performance of DexCom shows a 52-week-high of $659.45 and a 52-week-low of $318.45. Moreover, at the end of the last trading period, the closing price was at $435.67. For Glaukos Corp (NYSE: GKOS ), William Blair upgraded the previous rating of Market Perform to Outperform. For the third quarter, Glaukos had an EPS of $0.21, compared to year-ago quarter EPS of $0.09. The stock has a 52-week-high of $99.00 and a 52-week-low of $39.35. At the end of the last trading period, Glaukos closed at $52.90.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen, Inc. (NASDAQ: BIIB) shares

Ophthalmic medical company Glaukos Corporation (NYSE: GKOS ) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The data showed sustained and substantial reductions in intraocular pressure (IOP) in a 36-month analysis. The iDose TR contains formulated travoprost, a prostaglandin analog to reduce IOP. 70% and 68% of subjects in the fast- and slow-release iDose TR Full story available on Benzinga.com

Ophthalmic medical company Glaukos Corporation (NYSE: GKOS) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The data showed sustained and substantial re

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name Rencofilstat Hepion Pharmaceuticals, I

Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of the key jobs data for December. Investors are awaiting earnings results from Acuity Brands, Inc. (NYSE: AYI) and

Some of the stocks that may grab investor focus today are: Wall Street expects Acuity Brands, Inc. (NYSE: AYI) to report quarterly earnings at $2.41 per share on revenue of $880.70 million before t

Glaukos (GKOS) receives 510(k) clearance from the FDA for its iPRIME viscodelivery system

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

Stephens Inc. AR lifted its holdings in Glaukos Co. (NYSE:GKOS) by 80.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,922 shares of the medical instruments suppliers stock after purchasing an additional 2,638 shares during the period. Stephens Inc. ARs holdings in []

Glaukos Corporation (NYSE:GKOS) shares, rose in value on Friday, 12/17/21, with the stock price up by 4.41% to the previous days close as strong demand from buyers drove the stock to $43.78. Actively observing the price movement in the last trading, the stock closed the session at $41.93, falling within a range of $41.38 and Glaukos Corporation (NYSE: GKOS) Inclined 4.41%, Whats Next? Dont Be Too Excited Read More »

Related Stocks: ORSTED , DE , COUR , BBRI , CHR , BLI , GKOS ,